TOKYO, Japan, 28th April 2022 – EPS International Holdings Co., Ltd. (“EPS International” hereafter), a global CRO (Clinical Research Organization) with strength in Asia-Pacific clinical trials support, announced that EPS International completed a capital increase of EPS International Korea Ltd. (“EPS Korea” hereafter), one of its subsidiary companies, by way of third-party stock allotment to two Korean entrepreneurs.

As a result, Mr Seokmin YOON has become a major shareholder of EPS Korea and will be appointed as Representative Director and CEO of EPS Korea. Any other details, such as structures of the company (including company name) and relationship between EPS International and EPS Korea, remain unchanged.

Bringing to EPS Korea his wealth of clinical trials experience in South Korea, Mr YOON is expected to make a more robust clinical operation organization in Korea, providing the best solutions to our clients. In addition, Mr YOON will take advantage of his network with Korean pharmaceutical companies to explore and develop new business opportunities utilizing EPS Group’s* strength in Japan and Asia.

[Share of voting rights (shares) held by the major shareholders before and after the change]

Before change	After change
EPS International Holdings Co., Ltd. 100%	Seokmin YOON50.1% EPS International Holdings Co., Ltd. 35.0% Yunju CHOI14.9%

[Company overview]

Company name	EPS International Korea Ltd.
Name and title of representative	Seokmin YOON, Representative Director and CEO
Address	#1205 Seoulsup SKV1 tower 5, Seongsuil-ro-8 gil, Seongdong-gu Seoul, 04793, South Korea
Phone	+82 2 6385 3300

EPS International will continue to focus on creating new services under the corporate philosophy of the EPS Group: "EPS will contribute to the advancement of the healthcare industry by providing high-value- added solutions to our clients."

* [About EPS International and EPS Group]
Since its establishment in 1991 as one of the pioneering CROs in Japan and Asia, EPS Group has been a Healthcare Solution Provider to pharmaceutical companies, medical device manufacturers, hospitals, clinics, and academia. EPS solutions range from development to marketing, sales, consultation covering Asia, and new values created in big data & AI, regenerative medicine, etc. The strength of EPS International lies in the fact that it has great presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites, providing clinical development support services as well as SMO services.

[About Mr Seokmin YOON]
Mr Yoon is the chairman of the Korea Contract Research Organization Association (https://www.kcroa.or.kr/) and the founder of ADM Korea and Dream CIS, which are the major CROs in South Korea.

[Corporate Headquarters]
EPS International Holdings Co., Ltd.
Kagurazaka AK Bldg.
1-8 Tsukudocho, Shinjuku-ku
Tokyo 162-0821 Japan

Contact: contact-epsi@eps.co.jp
Websites:
EPS International: https://www.epsi-global.com/index.html
EPS Holdings: https://www.eps-holdings.co.jp/en/
LinkedIn: https://www.linkedin.com/company/eps-international/?viewAsMember=true

[For inquiries related to this news release]
Email: